This webinar includes a panel discussion of key topics in the field of cancer immunotherapy, including new and emerging methods, recent publications, and future directions. The links between preclinical research, in vivo studies, and biomarkers are explored, as well as the unique advantages of Crown Bioscience and their service offerings.
Key Topics Include:
- How our understanding of the cancer immunity cycle impacts cancer immunotherapy development
- Which new in vitro technologies provide more physiological and translatable drug responses
- Why HCI is providing deeper insights into drug responses
- What novel solutions are on the horizon to overcome the challenges of immunotherapeutic development
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Resources
Presenters
Director of Immuno-Oncology
Crown Bioscience
Trained as an immunologist, Gera Goverse has used novel technologies to study the role of different environmental factors on both the local and systemic immune system to suppress their responses in inflammatory disorders and in the field of immuno-oncology.
Since joining the team at Crown Bioscience, Gera has executed the design of many successful immuno-oncology projects to help national and international customers discover the full potential of their compounds.
Gera is motivated by studying the complex mechanisms of the regulation of the immune system, exploring tumor-cell interactions and refining ways to stimulate the immune responses towards the killing of the tumor.
Vice President
Research & Innovation
Crown Bioscience
As a pharmacologist with over 15 years of experience in the CRO/biotech industry and expertise in preclinical development of oncology drugs and vaccines, Ludovic is passionate about helping customers accelerate their early-stage drug development.
Senior Vice President of In Vitro, Head of Crown Bioscience Netherlands
Crown Bioscience
Leo Price leads Crown Bioscience’s in vitro services in Europe and the US and the Crown Bioscience sites in The Netherlands, Leiden and Utrecht. He joined Crown Bioscience in 2021 from OcellO, following Crown Bioscience’s acquisition of the company. Dr Price was the founder of OcellO, a leading provider of high content screening services, using organoids and other advanced 3D cell culture models, and served as their CEO and CSO for ten years.
Production Partner
Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology.
Additional Content From Crown Bioscience
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Human Biological Samples in Research: Quality, Compliance, and Clinical Relevance
In this webinar, three experts discuss best practices for ensuring specimen integrity, leveraging biobanking for oncology breakthroughs, and enriching clinical data for translational research.
Beyond Checkpoints: Strategic Use of CDX Models in Emerging IO Therapies
Learn how enhanced CDX models with humanized immune systems improve preclinical-to-clinical success in emerging immuno-oncology therapies.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
From Clinical Data to Actionable Assets for Pharmaceutical R&D
In this webinar, learn to transform raw clinical and biobanking data into research-ready assets to accelerate pharmaceutical R&D.